Acquisition by Carroll Michael A of 10000 shares of Nexalin Technology at 13.71 subject to Rule 16b-3

Read at macroaxis.com

Published 3 days ago View all stories for Nexalin Technology | Nexalin Technology Hype Analysis

Acquisition of 10000 common stock at 13.71 of Nexalin Technology by Carroll Michael A on 30th of November 2024. This event was filed by Nexalin Technology with SEC on 2006-08-24. Statement of changes in beneficial ownership - SEC Form 4

We analyze Nexalin Technology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nexalin Technology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nexalin Technology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Nexalin Technology stock to make a market-neutral strategy. Peer analysis of Nexalin Technology could also be used in its relative valuation, which is a method of valuing Nexalin Technology by comparing valuation metrics with similar companies.

Check out Nexalin Technology Hype Analysis, Nexalin Technology Correlation and Nexalin Technology Performance. For more information on how to buy Nexalin Stock please use our How to buy in Nexalin Stock guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nexalin Technology. If investors know Nexalin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nexalin Technology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Nexalin Technology is measured differently than its book value, which is the value of Nexalin that is recorded on the company's balance sheet. Investors also form their own opinion of Nexalin Technology's value that differs from its market value or its book value, called intrinsic value, which is Nexalin Technology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nexalin Technology's market value can be influenced by many factors that don't directly affect Nexalin Technology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Nexalin Technology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nexalin Technology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nexalin Technology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.